147 related articles for article (PubMed ID: 16740139)
1. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia.
Cervantes F; Alvarez-Larrán A; Hernández-Boluda JC; Sureda A; Granell M; Vallansot R; Besses C; Montserrat E
Br J Haematol; 2006 Jul; 134(2):184-6. PubMed ID: 16740139
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
Cervantes F; Alvarez-Larrán A; Hernández-Boluda JC; Sureda A; Torrebadell M; Montserrat E
Br J Haematol; 2004 Nov; 127(4):399-403. PubMed ID: 15521916
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.
Tsiara SN; Chaidos A; Bourantas LK; Kapsali HD; Bourantas KL
Acta Haematol; 2007; 117(3):156-61. PubMed ID: 17159338
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.
Cervantes F; Alvarez-Larrán A; Domingo A; Arellano-Rodrigo E; Montserrat E
Br J Haematol; 2005 Jun; 129(6):771-5. PubMed ID: 15953003
[TBL] [Abstract][Full Text] [Related]
5. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
Rodríguez JN; Martino ML; Diéguez JC; Prados D
Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
[TBL] [Abstract][Full Text] [Related]
6. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.
Musto P; Lanza F; Balleari E; Grossi A; Falcone A; Sanpaolo G; Bodenizza C; Scalzulli PR; La Sala A; Campioni D; Ghio R; Cascavilla N; Carella AM
Br J Haematol; 2005 Jan; 128(2):204-9. PubMed ID: 15638854
[TBL] [Abstract][Full Text] [Related]
7. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
Br J Haematol; 2006 Jun; 133(5):513-9. PubMed ID: 16681638
[TBL] [Abstract][Full Text] [Related]
8. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
9. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
Wanic-Kossowska M
Pol Merkur Lekarski; 2010 Jan; 28(163):13-7. PubMed ID: 20369716
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin treatment of idiopathic myelofibrosis.
Aloe Spiriti M; Latagliata R; Avvisati G; Battistel V; Montefusco E; Spadea A; Petti MC
Haematologica; 1993; 78(6):371-3. PubMed ID: 8175031
[TBL] [Abstract][Full Text] [Related]
11. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
12. [Importance of ultrapure dialysis liquid in response to the treatment of renal anaemia with darbepoetin in patients receiving haemodialysis].
Molina M; Navarro MJ; Palacios ME; de Gracia MC; García Hernández MA; Ríos Moreno F; Pérez Silva FM
Nefrologia; 2007; 27(2):196-201. PubMed ID: 17564565
[TBL] [Abstract][Full Text] [Related]
13. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
[TBL] [Abstract][Full Text] [Related]
15. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
16. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
Del Vecchio L; Villa G; Carraro G; Morosetti M; Pedrini L; Adorati Menegato M; Amato M; Mauro MM; Borgatti P; Malberti F; Marai P; Locatelli F;
G Ital Nefrol; 2004; 21(3):259-66. PubMed ID: 15285005
[TBL] [Abstract][Full Text] [Related]
17. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
Cancer; 2006 Dec; 107(12):2807-16. PubMed ID: 17115424
[TBL] [Abstract][Full Text] [Related]
18. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
Smith RE; Jaiyesimi IA; Meza LA; Tchekmedyian NS; Chan D; Griffith H; Brosman S; Bukowski R; Murdoch M; Rarick M; Saven A; Colowick AB; Fleishman A; Gayko U; Glaspy J
Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):24-30. PubMed ID: 11308271
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
20. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudi Arabia.
Shaheen FA; Akeel N; Alfi A; Harbi A; Tarif N; Souqiyyeh MZ
Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):365-72. PubMed ID: 16970257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]